<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>10(10)</volume><submitter>Xie X</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Numerous studies indicate that long noncoding RNA (lncRNA) is aberrantly expressed in ovarian cancer (OC). Our research investigated the regulatory role of lncRNA KTN1 antisense RNA1 (KTN1-AS1) in the progression of OC through the miR-505-3p/ZNF326 axis.&lt;h4>Methods&lt;/h4>Expression of &lt;i>KTN1-AS1&lt;/i>, microRNA-505-3p (&lt;i>miR-505-3p&lt;/i>), and zinc-finger protein-326 (&lt;i>ZNF326&lt;/i>) in OC was evaluated by using RT-qPCR analysis. The biological function of &lt;i>KTN1-AS1&lt;/i> was inspected using the loss-of-function assay. Luciferase reporter assay and RIP assay were performed to determine the competitive endogenous RNA (ceRNA) network of &lt;i>KTN1-AS1&lt;/i>/&lt;i>miR-505-3p&lt;/i>/&lt;i>ZNF326&lt;/i>.&lt;h4>Results&lt;/h4>The data showed that &lt;i>KTN1-AS1&lt;/i> and &lt;i>ZNF326&lt;/i> had a high expression in</pubmed_abstract><journal>Annals of translational medicine</journal><pagination>599</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9201172</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>H3K27ac-activated lncRNA KTN1-AS1 aggravates tumor progression by miR-505-3p/ZNF326 axis in ovarian cancer.</pubmed_title><pmcid>PMC9201172</pmcid><pubmed_authors>Yang X</pubmed_authors><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Zhang T</pubmed_authors><pubmed_authors>Xie X</pubmed_authors><pubmed_authors>Wen Q</pubmed_authors><pubmed_authors>Chen W</pubmed_authors><pubmed_authors>Xu C</pubmed_authors><pubmed_authors>Shi K</pubmed_authors><pubmed_authors>Liu W</pubmed_authors></additional><is_claimable>false</is_claimable><name>H3K27ac-activated lncRNA KTN1-AS1 aggravates tumor progression by miR-505-3p/ZNF326 axis in ovarian cancer.</name><description>&lt;h4>Background&lt;/h4>Numerous studies indicate that long noncoding RNA (lncRNA) is aberrantly expressed in ovarian cancer (OC). Our research investigated the regulatory role of lncRNA KTN1 antisense RNA1 (KTN1-AS1) in the progression of OC through the miR-505-3p/ZNF326 axis.&lt;h4>Methods&lt;/h4>Expression of &lt;i>KTN1-AS1&lt;/i>, microRNA-505-3p (&lt;i>miR-505-3p&lt;/i>), and zinc-finger protein-326 (&lt;i>ZNF326&lt;/i>) in OC was evaluated by using RT-qPCR analysis. The biological function of &lt;i>KTN1-AS1&lt;/i> was inspected using the loss-of-function assay. Luciferase reporter assay and RIP assay were performed to determine the competitive endogenous RNA (ceRNA) network of &lt;i>KTN1-AS1&lt;/i>/&lt;i>miR-505-3p&lt;/i>/&lt;i>ZNF326&lt;/i>.&lt;h4>Results&lt;/h4>The data showed that &lt;i>KTN1-AS1&lt;/i> and &lt;i>ZNF326&lt;/i> had a high expression in</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 May</publication><modification>2025-04-27T03:15:19.871Z</modification><creation>2025-04-06T18:45:34.387Z</creation></dates><accession>S-EPMC9201172</accession><cross_references><pubmed>35722429</pubmed><doi>10.21037/atm-22-443</doi></cross_references></HashMap>